{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:27:45Z","timestamp":1793824065012,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102057","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:03:00Z","timestamp":1791270180000},"page":"102057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seladelpar improves liver stiffness in PBC: ASSURE interim analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-6811","authenticated-orcid":false,"given":"Christopher L.","family":"Bowlus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra M.","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-3652","authenticated-orcid":false,"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elbeshbeshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-9784","authenticated-orcid":false,"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-948X","authenticated-orcid":false,"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-8134","authenticated-orcid":false,"given":"Yiannis","family":"Kallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-7990","authenticated-orcid":false,"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-8507","authenticated-orcid":false,"given":"Kyung min","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7253-2216","authenticated-orcid":false,"given":"Xin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria B.","family":"Crittenden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102057_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102057_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102057_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/apt.70391","article-title":"Treatment persistence, normal alkaline phosphatase and clinical outcomes in primary biliary cholangitis","volume":"63","author":"Kowdley","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.102057_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102057_bib7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102057_bib8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102057_bib10","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2025.09.024","article-title":"Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis","volume":"84","author":"Wong","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib12","unstructured":"LIVDELZI (seladelpar). Prescribing Information. Gilead Sciences, Inc. Foster City, California: 2024. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/pbc\/livdelzi\/livdelzi_pi.pdf. [Accessed 31 October 2025]."},{"key":"10.1016\/j.jhepr.2026.102057_bib13","unstructured":"LIVDELZI (seladelpar). Summary of Product Characteristics. Gilead Sciences, Inc. Foster City, California: 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/seladelpar-gilead-epar-product-information_en.pdf. [Accessed 31 October 2025]."},{"key":"10.1016\/j.jhepr.2026.102057_bib14","unstructured":"LIVDELZI 10 mg capsules. Summary of Product Characteristics. Gilead Sciences Ltd.\u202f London, UK: 2025. https:\/\/www.medicines.org.uk\/emc\/product\/100486\/smpc\/print. [Accessed 11 February 2026]."},{"key":"10.1016\/j.jhepr.2026.102057_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102057_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhepr.2026.102057_bib17","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.3390\/molecules29215189","article-title":"Selective PPAR\u03b4 agonist GW501516 protects against LPS-induced macrophage inflammation and acute liver failure in mice via suppressing inflammatory mediators","volume":"29","author":"Lim","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.jhepr.2026.102057_bib18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","volume":"121","author":"Levy","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102057_bib19","series-title":"Guideline for good clinical practice E6(R3)","year":"2025"},{"key":"10.1016\/j.jhepr.2026.102057_bib20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib21","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: Practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib22","article-title":"Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world","volume":"7","author":"Terracciani","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102057_bib23","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102057_bib24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.102057_bib25","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102057_bib26","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2024.10.020","article-title":"Noninvasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis","volume":"23","author":"Calvaruso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102057_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2026.03.038","article-title":"Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis","volume":"85","year":"2026","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:42:42Z","timestamp":1793821362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926003289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926003289"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102057","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seladelpar improves liver stiffness in PBC: ASSURE interim analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Gilead Sciences, Inc. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102057"}}